Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and is typically associated with chronic liver disease and cirrhosis. Advances in the diagnosis and treatment of HCC have led to increasingly diverse and personalized therapeutic options. Depending on the patient’s disease stage, liver function, and overall health status, different treatment strategies can significantly improve prognosis. Below is a detailed discussion of some of the main treatment options for HCC.
Surgical Resection
Surgical resection involves removing the tumor along with a portion of the surrounding healthy liver tissue. This treatment option is generally suitable for patients with a single or multiple tumors who have good liver function (Child-Pugh class A or B). Surgical resection offers a potential cure but is typically limited to patients without significant cirrhosis or portal hypertension. Postoperative complications may include liver failure and cancer recurrence.
Liver Transplantation
Liver transplantation is a viable treatment option for early-stage hepatocellular carcinoma (HCC) patients who meet the Milan criteria—defined as a single tumor measuring ≤5 cm or up to three tumors, each ≤3 cm—and have underlying cirrhosis. This procedure not only removes the tumor but also treats the underlying liver disease. However, the limited availability of donor organs poses a significant challenge, often resulting in prolonged waiting times for patients.
Local Treatments
• Radiofrequency Ablation (RFA): RFA utilizes high-frequency electrical currents to generate heat that destroys cancer cells. It is most effective for small tumors, typically less than 3 cm, and provides a minimally invasive alternative to surgery with a shorter recovery time. Potential complications include bleeding, infection, and damage to surrounding tissues.
• Transarterial Chemoembolization (TACE): TACE delivers chemotherapy drugs directly to the tumor’s blood supply and then blocks the artery to cut off blood flow to the tumor. It is used for intermediate-stage hepatocellular carcinoma (HCC) to shrink tumors for potential surgery or to relieve symptoms. Side effects may include pain, nausea, and liver dysfunction.
Systemic Treatments
• Targeted Drugs: Medications such as sorafenib and lenvatinib inhibit specific molecules involved in tumor growth and angiogenesis. They are used to treat advanced hepatocellular carcinoma (HCC) when surgery or local treatments are not feasible. Common side effects include hypertension, fatigue, and hand-foot skin reactions.
• Immunotherapy: Immune checkpoint inhibitors, such as nivolumab and pembrolizumab, enhance the body’s immune response against cancer cells. They are used to treat advanced hepatocellular carcinoma (HCC), especially when other treatments have failed. Side effects can range from mild (fatigue, rash) to severe (autoimmune reactions).
Multidisciplinary Collaboration
Optimal management of hepatocellular carcinoma (HCC) requires a multidisciplinary team, including oncologists, hepatologists, surgeons, radiologists, and transplant specialists. This team collaborates to develop personalized treatment plans based on each patient’s disease stage, liver function, and overall health, with the goal of improving survival rates and quality of life.